X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
MonoFerric injection having Ferric derisomaltose, is a rapid, single dose intravenous therapy used for the treatment of iron deficiency in adult patients when oral iron preparations are ineffective or cannot be used.
Lead Product(s): Ferric Derisomaltose
Therapeutic Area: Hematology Product Name: MonoFerric
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Pharmacosmos AS
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition September 09, 2022
Details:
Empagliflozin is used along with diet and exercise, and sometimes with other medications, to lower blood sugar levels in people with type 2 diabetes (condition in which blood sugar is too high because the body does not produce or use insulin normally).
Lead Product(s): Empagliflozin
Therapeutic Area: Endocrinology Product Name: Empagliflozin-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 04, 2022
Details:
Ivermectin is a Food and Drug Administration (FDA)-approved antiparasitic drug used to treat several neglected tropical diseases, including onchocerciasis, helminthiases, and scabies.
Lead Product(s): Ivermectin
Therapeutic Area: Dermatology Product Name: Ivermectin-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 04, 2022
Details:
Phase 3 interim clinical trial data of their plasmid DNA vaccine ZyCoV-D, highlights the overall effectiveness and protective efficacy against COVID-19 in expanded age groups when administered intradermally with the Tropis® intradermal System.
Lead Product(s): ZyCoV-D
Therapeutic Area: Infections and Infectious Diseases Product Name: ZyCoV-D
Highest Development Status: Phase IIIProduct Type: Vaccine
Recipient: PharmaJet
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 27, 2022
Details:
About 91 per cent of patients treated with the Pegylated Interferon Alpha-2b, tested negative for Covid-19 in standard RT-PCR tests by day seven, compared to nearly 79 per cent who were given the standard of care, the company said earlier this month.
Lead Product(s): Pegylated Interferon Alpha-2b
Therapeutic Area: Infections and Infectious Diseases Product Name: PegiHep
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 23, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
